# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, develo...
As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Bioscie...
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious diseas...